Publications in collaboration with researchers from Liverpool Hospital (16)

2024

  1. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    PLOS Digital Health, Vol. 3, Núm. 7

2023

  1. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

    Neurodegenerative Disease Management, Vol. 13, Núm. 4, pp. 215-221

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

    Multiple Sclerosis Journal, Vol. 29, Núm. 2, pp. 221-235

  4. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  5. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

2021

  1. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2020

  1. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

2019

  1. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468

2017

  1. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

  2. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349